Among others, SAM Holdings will help EnGeneIC secure funding and regulatory authorisations for building a manufacturing plant in Singapore to manufacture EDV-based products and conduct clinical trials in the city-state. In turn, SAM Holdings will be granted exclusive distribution and marketing rights of these products in 17 countries within Asia.
Catalist-listed Singapore Institute of Advanced Medicine Holdings (SAM Holdings) has entered into a strategic partnership with Australia-based biopharmaceutical company EnGeneIC.
Under the partnership, SAM Holdings will collaborate with EnGeneIC on a profit-sharing basis for manufacturing and distribution of anti-cancer products based on the latter’s proprietary technology platform, EnGeneIC Dream Vector (EDV). The partnership will also involve the development of EDV-based theranostics for use in the imaging and treatment of various cancers.
